University of California San Francisco

Clinical Trials

Data provided by UCSF Profiles, powered by CTSI
  1. DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (NCT06075953)
    Related Conditions: Ductal Carcinoma in Situ, Breast Cancer, Carcinoma| Start Date: | End Date:
  2. I CAN DO Surgical ACP (NCT06090552)
    Related Conditions: End of Life| Start Date: | End Date:
  3. Statins and Breast Cancer Biomarkers (NCT00914017)
    Related Conditions: Breast Cancer| Start Date:
  4. Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction (NCT01258296)
    Related Conditions: Postoperative Pain| Start Date: | End Date:
  5. Study of Ductal Lavage in Women at High Risk for Breast Cancer (NCT00429988)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  6. Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery (NCT00033397)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  7. Intraoperative Use of ClearEdge Device in Breast Conserving Surgery (NCT05456373)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  8. Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (NCT04821141)
    Related Conditions: Breast Cancer, Menopause| Start Date: | End Date:
  9. I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (NCT04488081)
    Related Conditions: COVID-19| Start Date: | End Date:
  10. Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) (NCT02872025)
    Related Conditions: Carcinoma, Intraductal, Noninfiltrating, Immunotherapy, Carcinoma| Start Date: | End Date:
  11. Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (NCT02620852)
    Related Conditions: Breast Cancer, Cancer, General| Start Date: | End Date:
  12. Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast (NCT00788112)
    Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:
  13. Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (NCT00416403)
    Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:
  14. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (NCT03053193)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  15. PCORI-1502-27462 Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment (NCT02623335)
    Related Conditions: Communication| Start Date: | End Date:
  16. Biofeedback Treatment for Functional Constipation (NCT00502957)
    Related Conditions: Constipation, Functional Constipation| Start Date: | End Date:
  17. UCSF PANC Cyst Registry (NCT04291651)
    Related Conditions: Pancreatic Cyst, Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Diseases, Intraductal Papillary Mucinous Neoplasm, Pancreatic Ductal Adenocarcinoma, Neoplasms| Start Date: | End Date:
  18. Comparing Two Methods to Follow Patients With Pancreatic Cysts (NCT04239573)
    Related Conditions: Pancreatic Cancer, Pancreatic Cyst, Pancreatic Neoplasms| Start Date: | End Date:
  19. Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors (NCT05746208)
    Related Conditions: Neuroendocrine Tumor, Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
  20. Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (NCT05746182)
    Related Conditions: Pancreatic Neuroendocrine Neoplasm, Neoplasms, Neuroendocrine Tumor| Start Date: | End Date:
  21. Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas (NCT03136055)
    Related Conditions: Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
  22. Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (NCT01841736)
    Related Conditions: Neuroendocrine Tumor, Carcinoid Tumor, Neoplasms, Pancreatic Cancer, Pancreatic Neoplasms, Stomach Cancer, Gastrointestinal Cancer| Start Date: | End Date:
  23. RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (NCT00843531)
    Related Conditions: Neuroendocrine Tumor| Start Date: | End Date:
  24. Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors (NCT00390156)
    Related Conditions: Solid Tumor, Neoplasms| Start Date: | End Date:
  25. Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (NCT00227617)
    Related Conditions: Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor, Neoplasms, Gastrointestinal Cancer| Start Date: | End Date: